Mat Legut, PhD

Unconventional T cell biologist and genome engineer. Previously @cardiffuni @nyuniversity @nygenome 🏳️‍🌈

[Mat Legut, PhD @MatLegut]

After some time in the making, I am really happy to announce @OverT_Bio’s official launch today. I am excited and humbled by the experience of building OverT with a terrific team of scientists and operators #startup #celltherapy #cancer

[OverT Bio @OverT_Bio]

We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.

https://t.co/mKj8OiXrk0

[OverT Bio @OverT_Bio]

Excited to share a big milestone for OverT Bio—we’ve formed our Clinical Advisory Board.

Grateful to partner with an incredible group of leaders as we build scalable γδ CAR-T therapies for solid tumors.

https://t.co/NqeIFVIilG

[Júlia Domingo @JuliaDiumenge]

Come and join the extraordinary team of ALLOX and help us accelerate the discovery of more effective therapies!
👉https://t.co/nUjV6wH9Ae

[Cancer Research Institute @CancerResearch]

🎉Congratulations to the team at @OverT_Bio and its co-founders, @MatLegut and former CRI Tech Impact Award Grantee @nevillesanjana on the company's debut! Learn more in @endpts:

[Neville Sanjana @nevillesanjana]

Congrats to @MatLegut & the entire @OverT_Bio team! Grateful for the opportunity to translate discoveries from our lab @nygenome & @nyuniversity into therapies for cancer patients.

Thrilled to be a part of this amazing team — onward and upward! 🚀

[Mat Legut, PhD @MatLegut]

@nevillesanjana @ArtisVentures @Wing_VC @FusionFundVC @CivilizationVC @GaingelsVC @CancerResearch Last but not least, special mention to our first investors who supported us from the very start of this journey: Jim Magid, Dr. Anthony Evnin and Jeanette Cone Kimmel

[Mat Legut, PhD @MatLegut]

After some time in the making, I am really happy to announce @OverT_Bio’s official launch today. I am excited and humbled by the experience of building OverT with a terrific team of scientists and operators #startup #celltherapy #cancer

[OverT Bio @OverT_Bio]

We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.

https://t.co/mKj8OiXrk0

[Mat Legut, PhD @MatLegut]

Shout-out to my co-founder @nevillesanjana and our partners at @ArtisVentures @Wing_VC @FusionFundVC OMX, Alexandria Venture Investments, @CivilizationVC @GaingelsVC @CancerResearch and Hawktail

[OverT Bio @OverT_Bio]

We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers.

https://t.co/mKj8OiXrk0

[Júlia Domingo @JuliaDiumenge]

Big news!! I can finally officially announce that a few weeks ago, ALLOX @ALLOXbio was co-founded by the brilliant André Faure @aj4re , Pablo Baeza @pbcenturion , Ben Lehner @BenLehner , and myself, who will be stepping in as CEO of the company.

[Mat Legut, PhD @MatLegut]

Looking forward to hearing about latest breakthroughs in cancer therapy and making new connections! @ASCO #ASCOBT23

[T-cell Modulation Group @TcellResearch]

Great effort from the team on this study published in Cell today! Hard work pays off - well done everyone 👏🏻

Exciting science - discovering new T-cell receptors for cancer immunotherapies 🔬

#cancerimmunotherpies #cellscience #tcells

https://t.co/6zzD0IVUeP

[Mat Legut, PhD @MatLegut]

Shoutout to @TcellResearch team for this beautiful study! Super happy to have been able to contribute a small part to this work. Hoping this discovery will bring about #tcr #celltherapy to more patients with hard to treat cancers! #immunotherapy

[Mat Legut, PhD @MatLegut]

A really exciting article, fresh from the press @CellCellPress! T cells are indeed #crossreactive, in this case a single T cell receptor can bind and recognise distinct cancer antigens from not one, but three proteins (or more!).

https://t.co/DuI5VPW56b

[T-cell Modulation Group @TcellResearch]

For anyone interested in our work and our team - we would greatly appreciate extra votes in the following competition! Voting is open until the 4th July 🗳️🙏🏻🧬🧪

MolecularCloud | 2023 Distinguished Research Awards for Gene and Cell Therapy https://t.co/cBgTGUJns0

[Neville Sanjana @nevillesanjana]

I had some fun taking my #ScienceTwitter game to the next level with @WIRED 🐦🎮👨‍🔬 🙂

And several awesome CRISPR questions too!✂️🧬

[Mat Legut, PhD @MatLegut]

Grateful for being invited to participate in the new Tools of the trade series from @NatureRevCancer, highlighting our recent study on developing new #immunotherapy for cancer through genome-scale screens in #tcells

[Nature Reviews Cancer @NatureRevCancer]

NEW content online! Multiomics-guided cellular immunotherapies https://t.co/IaBy9FXk1L

[Nature Reviews Cancer @NatureRevCancer]

NEW content online! Multiomics-guided cellular immunotherapies https://t.co/IaBy9FXk1L

[Mat Legut, PhD @MatLegut]

Great to see we got through the first round! Now let’s go and win the second one!

[New York University @nyuniversity]

.@nevillesanjana and colleagues from NYU and @nygenome developed a genetic screening platform to identify genes that transform immune cells into more aggressive cancer fighters. Their promising study was published in @Nature. Vote for it in #statmadness: https://t.co/bwuTtA154P

[New York University @nyuniversity]

.@nevillesanjana and colleagues from NYU and @nygenome developed a genetic screening platform to identify genes that transform immune cells into more aggressive cancer fighters. Their promising study was published in @Nature. Vote for it in #statmadness: https://t.co/OxrmwAJGq4

[Mat Legut, PhD @MatLegut]

Super excited to see our research on building new immunotherapies getting picked by @statnews to represent @nyuniversity

(Also, turns out this March Madness is like an actual sports thing! Things you learn… 🤷🏻‍♂️)

https://t.co/tUHJWoAUeb